A unique Rare Disease Partner Model

We selected Sobi on the strength of their Specialty Care and Rare Disease Partner Model and their demonstrated understanding of the needs of patients, health care providers and payers in the regions they cover. Through our partnership with Sobi, we were able to successfully introduce COMETRIQ to the medullary thyroid cancer clinical community in Europe with minimal commercial risk and without the large-scale direct investment that would’ve been required to establish our own European capabilities and infrastructure. Sobi’s rare disease expertise and commercial presence across the region made them an ideal partner.

Michael M. Morrissey Ph.D. , President and Chief Executive Officer Exelixis, Inc.

Partner with us

We are looking for new partners. Improving patient health in new territories and providing business success to our partners is what Sobi Partner Products does. We think that the right pharmaceutical product in the best hands is a perfect match. We would love to work with you.

Read more about partnering with us


07 Dec 2016

Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Horizon Pharma plc (NASDAQ: HZNP) (“Horizon”) today announced that the companies have entered into a...

07 Jan 2016

Sobi gains commercial rights for Relistor®, Deflux® and Solesta® from PharmaSwiss

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the company has gained commercial rights from the Swiss based company...

Read more